While Encysive Pharmaceuticals Inc. received a third approvable letter for Thelin (sitaxsentan sodium) on Friday, Gilead Sciences Inc. got approval for Letairis (ambrisentan), a competing endothelin A receptor antagonist for pulmonary arterial hypertension (PAH). (See Encysive story this issue).(BioWorld Today)